Comparison of One-Year Outcomes in Patients >75 Versus ≤75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry)
Section snippets
Methods
The MASCOT registry (clinicaltrials.gov identifier NCT02183454) was a post marketing observational study conducted to evaluate the long-term safety and performance of the COMBO stent in routine clinical practice.1 Patients were enrolled in 60 sites across Europe, Middle East, Asia, and South America. The study design has been previously described and the study was managed by the Clinical Coordinating Center at the Icahn School of Medicine at Mount Sinai with full oversight of the study
Results
Of the study cohort, 18% (n = 479) patients were >75 years and 72% (n = 2,135) were ≤75years of age. Table 1 shows the baseline characteristics of the 2 groups. Elderly patients included more women and had lower body mass index with higher prevalence of several comorbidities including hypertension, chronic kidney disease, anemia and congestive heart failure but lower prevalence of current smokers. With respect to vascular disease older patients had greater prevalence of prior stroke, peripheral
Discussion
The main findings of this analysis comparing patients >75 years and those ≤75 years of age from the all-comers MASCOT registry treated with COMBO stents are as follows: 1. Elderly patients had a greater prevalence of several baseline comorbidities, and included more women, however, they presented less often with ST-segment elevation myocardial infarction; 2. there were no differences in the rates of radial access PCI, or implanted stent size in elderly compared with younger patients. The use of
Disclosures
The authors declare that they have no known competing financial interests or personal relations that could have appeared to influence the work reported in this study.
References (24)
- et al.
Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry
Int J Cardiol
(2019) - et al.
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study
Lancet
(2013) - et al.
National trends and outcomes of percutaneous coronary intervention in patients >/=70 years of age with acute coronary syndrome (from the National Inpatient Sample Database)
Am J Cardiol
(2019) - et al.
Management of patients aged >/=85 years with ST-elevation myocardial infarction
Am J Cardiol
(2016) - et al.
Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial
Lancet
(2018) - et al.
Drug-coated versus bare-metal stents for elderly patients: a predefined sub-study of the LEADERS FREE trial
Int J Cardiol
(2017) - et al.
Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS
J Am Coll Cardiol
(2016) - et al.
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials
Lancet
(2017) - et al.
Dual-Antiplatelet therapy cessation and cardiovascular risk in relation to age: analysis from the PARIS registry
JACC Cardiovasc Interv
(2019) - et al.
Early discontinuation of dual antiplatelet therapy in patients treated with the bio-engineered pro-healing sirolimus-eluting (COMBO) stent
Cardiovasc Revasc Med
(2018)
Temporal trends in the treatment and outcomes of elderly patients with acute coronary syndrome
Eur Heart J
Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study
Clin Res Cardiol
Cited by (0)
The MASCOT registry was sponsored by OrbusNeich Medical (Ft. Lauderdale, Florida).
Dr. Mehran has received institutional research grant support from Eli Lilly/Daiichi-Sankyo Inc., AstraZeneca, The Medicines Company, Bristol-Myers Squibb, OrbusNeich, Beth Israel Deaconess, and Bayer; has served as a consultant for Boston Scientific, Cardiovascular Systems Inc., Medscape, and Shanghai BraccoSine Pharmaceutical; has received institutional advisory board funding from Bristol-Myers Squibb; has received institutional funding from Claret Medical; owns equity in Claret Medical and Elixir Medical; has served on the executive committee for Janssen Pharmaceuticals and Osprey Medical; has served on the data safety monitoring board for Watermark Research Partners; and has a spouse who has served as a consultant for Abiomed and the Medicines Company. Dr. Kala has served as a consultant for Boston Scientific; has received research support from Astra Zeneca, Novartis, Zoll; has served on advisory board for Astra Zeneca, Bayer, Medtronic and Boston Scientific. All other authors have reported that they have no relations relevant to the contents of this study to disclose.
Clinicaltrials.gov identifier: NCT02183454.